Article Text

other Versions

Download PDFPDF
Peginterferon alfa-2a (40KD) plus ribavirin in chronic hepatitis C patients who failed previous interferon therapy

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

PDF extract preview

This is a PDF-only article. The first page of the PDF of this article appears above.

Supplementary materials

  • Competing interests: MS, advisor and speakers bureau for Roche.
    EMY, Honoraria for lectures sponsored by Roche and Schering Plough; Advisor to Roche; Unrestricted research grants from Roche, Schering Plough, Fujisawa, Pfizer, GlaxoSmithKline; Investigator in trials sponsored by Roche, Schering Ploughm Human Genome Sciences, Idenix, Microgenix, Fujisawa, Novartis, Wyeth.
    MD, no conflicts of interest to declare.
    MK, unrestricted research grants from Roche, Schering Plough.
    VGB, no conflicts of interest to declare.
    KP, no conflicts of interest to declare.
    FA, no conflicts of interest to declare.
    KK, no conflicts of interest to declare.
    SS, Roche employee.
    SSL, research grants from Roche, speakers bureau and consulting for Roche.